CN110461351B - 用tlr2激动剂治疗呼吸道感染 - Google Patents

用tlr2激动剂治疗呼吸道感染 Download PDF

Info

Publication number
CN110461351B
CN110461351B CN201880020768.1A CN201880020768A CN110461351B CN 110461351 B CN110461351 B CN 110461351B CN 201880020768 A CN201880020768 A CN 201880020768A CN 110461351 B CN110461351 B CN 110461351B
Authority
CN
China
Prior art keywords
pam2cys
compound
peg
infection
hrv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880020768.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110461351A (zh
Inventor
N·巴特利特
J·吉尔金
D·杰克逊
W·曾
I·霍尔姆斯
C·德迈松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aina Breathing Pte Ltd
Original Assignee
Aina Breathing Pte Ltd
Ena Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901180A external-priority patent/AU2017901180A0/en
Application filed by Aina Breathing Pte Ltd, Ena Therapeutics Pty Ltd filed Critical Aina Breathing Pte Ltd
Priority to CN202410307367.1A priority Critical patent/CN118161614A/zh
Publication of CN110461351A publication Critical patent/CN110461351A/zh
Application granted granted Critical
Publication of CN110461351B publication Critical patent/CN110461351B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201880020768.1A 2017-03-31 2018-03-29 用tlr2激动剂治疗呼吸道感染 Active CN110461351B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410307367.1A CN118161614A (zh) 2017-03-31 2018-03-29 用tlr2激动剂治疗呼吸道感染

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2017901180A AU2017901180A0 (en) 2017-03-31 Treatment of respiratory infection
AU2017901180 2017-03-31
AU2017905124A AU2017905124A0 (en) 2017-12-21 Treatment of respiratory infection (2)
AU2017905128 2017-12-21
AU2017905128A AU2017905128A0 (en) 2017-12-21 Optimised compounds
AU2017905124 2017-12-21
AU2018900409A AU2018900409A0 (en) 2018-02-09 Treatment of respiratory infection (3)
AU2018900409 2018-02-09
PCT/AU2018/050295 WO2018176099A1 (en) 2017-03-31 2018-03-29 Treatment of respiratory infection with a tlr2 agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410307367.1A Division CN118161614A (zh) 2017-03-31 2018-03-29 用tlr2激动剂治疗呼吸道感染

Publications (2)

Publication Number Publication Date
CN110461351A CN110461351A (zh) 2019-11-15
CN110461351B true CN110461351B (zh) 2024-03-26

Family

ID=63673872

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880020768.1A Active CN110461351B (zh) 2017-03-31 2018-03-29 用tlr2激动剂治疗呼吸道感染
CN202410307367.1A Pending CN118161614A (zh) 2017-03-31 2018-03-29 用tlr2激动剂治疗呼吸道感染

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410307367.1A Pending CN118161614A (zh) 2017-03-31 2018-03-29 用tlr2激动剂治疗呼吸道感染

Country Status (8)

Country Link
US (1) US20200147028A1 (enExample)
EP (1) EP3600374B1 (enExample)
JP (2) JP7719590B2 (enExample)
CN (2) CN110461351B (enExample)
AU (1) AU2018241248B2 (enExample)
ES (1) ES2979287T3 (enExample)
PL (1) PL3600374T3 (enExample)
WO (1) WO2018176099A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
IL275360B2 (en) * 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
WO2019119069A1 (en) * 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent
NZ783377A (en) * 2019-06-26 2026-03-27 Ena Respiratory Pty Ltd Pegylated novel molecules for agonising tlr2
WO2021042174A1 (en) * 2019-09-04 2021-03-11 Ena Therapeutics Pty Ltd Cancer treatment
JP2022546806A (ja) * 2019-09-04 2022-11-09 アクセリア オンコロジー ピーティーワイ リミテッド 癌免疫療法
US20230346829A1 (en) * 2020-05-11 2023-11-02 Revir, Inc. Compositions and methods for treating viral infections
AU2021278377A1 (en) * 2020-05-26 2022-12-15 Ena Respiratory Pty Ltd Treatment of coronavirus
AU2021294603A1 (en) * 2020-06-26 2022-12-15 Ena Respiratory Pty Ltd Branched lipid compounds
EP4395761A4 (en) * 2021-08-31 2025-10-01 Ena Respiratory Pty Ltd ALLERGY TREATMENT
AU2022338350A1 (en) * 2021-09-02 2024-02-29 Ena Respiratory Pty Ltd Formulation
CN114539356B (zh) * 2022-02-21 2023-06-09 中国人民解放军陆军军医大学 一种脂肽及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115430A1 (en) * 2004-05-27 2005-12-08 Gropep Limited Treatment of inflammatory airway disease
WO2009137103A2 (en) * 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
WO2011119759A1 (en) * 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2013049941A1 (en) * 2011-10-06 2013-04-11 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
WO2016037240A1 (en) * 2014-09-12 2016-03-17 The University Of Melbourne Immunological reagent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119856A1 (de) 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
WO2005079419A2 (en) * 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
CA2811957C (en) * 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115430A1 (en) * 2004-05-27 2005-12-08 Gropep Limited Treatment of inflammatory airway disease
WO2009137103A2 (en) * 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
WO2011119759A1 (en) * 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
CN102905703A (zh) * 2010-03-23 2013-01-30 Irm责任有限公司 作为tlr2激动剂用于治疗感染、炎症、呼吸疾病等的化合物(基于半胱氨酸的脂肽)和组合物
WO2013049941A1 (en) * 2011-10-06 2013-04-11 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
WO2016037240A1 (en) * 2014-09-12 2016-03-17 The University Of Melbourne Immunological reagent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice;Amabel C.L等;《MOLECULAR PHARMACEUTICS》;20120803;第9卷(第9期);第2710-2718页 *
The activity of lipopeptide TLR2 agonists critically depends on the presence of solubilizers;Söhnke Voss等;《European journal of Immunology》;20071231;第37卷(第12期);第3489-3498页 *
Toll样受体与支气管哮喘关系的研究进展;陆嘉玮;王谦;赵祥安;朱佳;;山东医药;20170324(12);110-113 *
β_2肾上腺素受体激活与气道炎症的研究进展;王伟;胥婕;贺蓓;;实用医学杂志;20131110(21);180-181 *

Also Published As

Publication number Publication date
PL3600374T3 (pl) 2024-09-23
JP2020512336A (ja) 2020-04-23
AU2018241248A1 (en) 2019-09-05
CN118161614A (zh) 2024-06-11
JP7719590B2 (ja) 2025-08-06
EP3600374A1 (en) 2020-02-05
CN110461351A (zh) 2019-11-15
EP3600374C0 (en) 2024-05-15
US20200147028A1 (en) 2020-05-14
JP7795489B2 (ja) 2026-01-07
AU2018241248B2 (en) 2025-01-23
EP3600374A4 (en) 2021-01-20
JP2023081969A (ja) 2023-06-13
WO2018176099A1 (en) 2018-10-04
EP3600374B1 (en) 2024-05-15
ES2979287T3 (es) 2024-09-25

Similar Documents

Publication Publication Date Title
JP7795489B2 (ja) Ｔｌｒアゴニストによる呼吸器感染症の治療
JP7439367B2 (ja) 最適化化合物
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
JP2019512506A (ja) 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ
WO2009039310A2 (en) Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
US20230226004A1 (en) Treatment of coronavirus
US20240269242A1 (en) Compositions and methods for treating and preventing lung disease
US20250171511A1 (en) Antiviral peptides and methods of use thereof
JP2024532434A (ja) 製剤
US20200299331A1 (en) Composition Comprising a Peptide and an Inhibitor of Viral Neuraminidase
KR20240052799A (ko) 폐질환을 치료 및 예방하기 위한 조성물 및 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Australia, Vitoria

Applicant after: Axelia oncology Pte. Ltd.

Address before: Australia, Vitoria

Applicant before: Ena Therapeutics Pty Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20221223

Address after: New South Wales,Australia

Applicant after: Aina Breathing Pte. Ltd.

Address before: Australia, Vitoria

Applicant before: Axelia oncology Pte. Ltd.

GR01 Patent grant
GR01 Patent grant